Prime Medicine, Inc.
PRME
$3.55
$0.3310.25%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 146.02% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 146.02% | -- | -- | -- |
| Cost of Revenue | -23.76% | 4.81% | -17.74% | -1.53% | -87.80% |
| Gross Profit | 50.18% | 34.30% | 23.01% | 2.04% | 87.80% |
| SG&A Expenses | 4.09% | 19.05% | -5.98% | 34.40% | 18.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.12% | 10.04% | -14.92% | 5.79% | 23.01% |
| Operating Income | 4.12% | -8.38% | 18.92% | -5.39% | -23.01% |
| Income Before Tax | 5.17% | -13.73% | 35.60% | -3.35% | -30.95% |
| Income Tax Expenses | -- | -- | -- | -- | -532.26% |
| Earnings from Continuing Operations | 4.95% | -13.39% | 35.60% | -3.57% | -30.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.95% | -13.39% | 35.60% | -3.57% | -30.53% |
| EBIT | 4.12% | -8.38% | 18.92% | -5.39% | -23.01% |
| EBITDA | 4.84% | -7.80% | 20.25% | -4.88% | -22.64% |
| EPS Basic | 12.30% | 9.47% | 54.51% | 20.58% | 0.92% |
| Normalized Basic EPS | 11.75% | 14.22% | 44.11% | 19.39% | 6.33% |
| EPS Diluted | 12.30% | 9.47% | 54.51% | 20.58% | 0.92% |
| Normalized Diluted EPS | 11.75% | 14.22% | 44.11% | 19.39% | 6.33% |
| Average Basic Shares Outstanding | 8.39% | 25.29% | 41.59% | 30.40% | 31.75% |
| Average Diluted Shares Outstanding | 8.39% | 25.29% | 41.59% | 30.40% | 31.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |